168 related articles for article (PubMed ID: 35916608)
1. Comparison of orexin-A and neurofilament light chain levels in patients with relapsing-remitting multiple sclerosis: a pilot study.
Saruhan E; Korkmaz M; Altiparmak B; Tosun K; Kutlu G
Ideggyogy Sz; 2022 Jul; 75(7-08):223-230. PubMed ID: 35916608
[TBL] [Abstract][Full Text] [Related]
2. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
Arroyo Pereiro P; Muñoz-Vendrell A; León Moreno I; Bau L; Matas E; Romero-Pinel L; Martínez Yélamos A; Martínez Yélamos S; Andrés-Benito P
J Neurol; 2024 Apr; 271(4):1599-1609. PubMed ID: 38085343
[TBL] [Abstract][Full Text] [Related]
3. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
Kuhle J; Barro C; Disanto G; Mathias A; Soneson C; Bonnier G; Yaldizli Ö; Regeniter A; Derfuss T; Canales M; Schluep M; Du Pasquier R; Krueger G; Granziera C
Mult Scler; 2016 Oct; 22(12):1550-1559. PubMed ID: 26754800
[TBL] [Abstract][Full Text] [Related]
4. The effect of aerobic exercise on Neurofilament light chain and glial Fibrillary acidic protein level in patients with relapsing remitting type multiple sclerosis.
Ercan Z; Bilek F; Demir CF
Mult Scler Relat Disord; 2021 Oct; 55():103219. PubMed ID: 34433118
[TBL] [Abstract][Full Text] [Related]
5. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
Sejbaek T; Nielsen HH; Penner N; Plavina T; Mendoza JP; Martin NA; Elkjaer ML; Ravnborg MH; Illes Z
J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1324-1330. PubMed ID: 31611264
[TBL] [Abstract][Full Text] [Related]
6. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
[TBL] [Abstract][Full Text] [Related]
7. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
Håkansson I; Johansson L; Dahle C; Vrethem M; Ernerudh J
Mult Scler Relat Disord; 2019 Nov; 36():101424. PubMed ID: 31586802
[TBL] [Abstract][Full Text] [Related]
8. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
9. Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis.
Rosenstein I; Rasch S; Axelsson M; Novakova L; Blennow K; Zetterberg H; Lycke J
Front Immunol; 2022; 13():967953. PubMed ID: 36032114
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
[TBL] [Abstract][Full Text] [Related]
11. Long-term prognostic value of longitudinal measurements of blood neurofilament levels.
Häring DA; Kropshofer H; Kappos L; Cohen JA; Shah A; Meinert R; Leppert D; Tomic D; Kuhle J
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32817406
[TBL] [Abstract][Full Text] [Related]
12. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.
Filippi P; Vestenická V; Siarnik P; Sivakova M; Čopíková-Cudráková D; Belan V; Hanes J; Novák M; Kollar B; Turcani P
Neuro Endocrinol Lett; 2020 Apr; 41(1):17-26. PubMed ID: 32338853
[TBL] [Abstract][Full Text] [Related]
13. A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course.
Huss A; Otto M; Senel M; Ludolph AC; Abdelhak A; Tumani H
Front Neurol; 2020; 11():608. PubMed ID: 32765393
[No Abstract] [Full Text] [Related]
14. Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.
de Flon P; Laurell K; Sundström P; Blennow K; Söderström L; Zetterberg H; Gunnarsson M; Svenningsson A
Acta Neurol Scand; 2019 May; 139(5):462-468. PubMed ID: 30740668
[TBL] [Abstract][Full Text] [Related]
15. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
[TBL] [Abstract][Full Text] [Related]
17. Serum neurofilament light chain is more strongly associated with T2 lesion volume than with number of T2 lesions in patients with multiple sclerosis.
Wenger KJ; Hoelter MC; Yalachkov Y; Hendrik Schäfer J; Özkan D; Steffen F; Bittner S; Hattingen E; Foerch C; Schaller-Paule MA
Eur J Radiol; 2023 Sep; 166():111019. PubMed ID: 37549559
[TBL] [Abstract][Full Text] [Related]
18. Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.
Rosenstein I; Axelsson M; Novakova L; Blennow K; Zetterberg H; Lycke J
Mult Scler; 2022 May; 28(6):872-884. PubMed ID: 34392718
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Kuhle J; Disanto G; Lorscheider J; Stites T; Chen Y; Dahlke F; Francis G; Shrinivasan A; Radue EW; Giovannoni G; Kappos L
Neurology; 2015 Apr; 84(16):1639-43. PubMed ID: 25809304
[TBL] [Abstract][Full Text] [Related]
20. Serum neurofilament light chain in relapsing multiple sclerosis patients on a ketogenic diet.
Oh U; Woolbright E; Lehner-Gulotta D; Coleman R; Conaway M; Goldman MD; Brenton JN
Mult Scler Relat Disord; 2023 May; 73():104670. PubMed ID: 36996634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
